All the Active Ingredient Drugs
Monoclonal Antibody, VEGF Inhibitor. Bevacizumab 25 mg/ml. VIALS: 1 x 100 mg/4 ml; 1 x 400
mg/16ml.
Dosage adjust. individ. for each pt.
accord to the med. cond. accord. to
prescr. info.
Tmt. metastat. Carcinoma of the colon or
rectum, to be used in combinat. With
fluoropyrimidine-based chemother.
Firstline tmt. metastat. Breast cancer, in
comb. with Paclitaxel. tmt.
unresect.,advanced, metastat./recurrent
NSCLC other than predom. squamous cell
histology, in add. to platinum-based
chemother. tmt. advanc./metastat. Renal
cell cancer, in comb. with interferon alfa-
2a. Firstline tmt. advanc./metastat. Renal
cell cancer, in comb. with interferon alfa-
2a. As single agent tmt. glioblastom. In
pts. with progress. dis. foll. prior ther.
Front-line tmt. in comb. with paclitaxel.
and carboplatin advanc. (FIGO III B, III
C,IV) epithelial ovar., fallop. tube, or
primary peritoneal canc. in pts at high risk
for recurrence (resid. dis. aft.debulk.). in
comb. with carboplatin and gemcitabine
tmt of adult pts. with first recur.of
platinum-sensit. epithelial ovar., fallopian
tube or prim. peritoneal cancer who have
not received prior therapy with
Bevacizumab or other VEGF inhibit. or
VEGF receptor–targeted agents.
C/I: Hypersens. active substance/
excips./ chinese hamster ovary/ other recombinant human or humanized
antibodies., pregn.
